National Academies Press: OpenBook
« Previous: Appendix A Workshop Agenda
Suggested Citation:"Appendix B Workshop Speakers, Moderators, Invited Discussants, and Participants." Institute of Medicine. 2006. Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11768.
×

Appendix B
Workshop Speakers*, Moderators†, Invited Discussants‡, and Participants

David Agus, Cedars-Sinai Medical Center‡

Naomi Aronson, BlueCross BlueShield Technology Evaluation Center*†

Suresh Arya, National Institutes of Health

Finley Austin, Roche Pharmaceuticals

Rekha Ayalur, Digene Corporation

Chris Beecher, Metabolon

Al Berg, University of Washington*†

Amy Brownawell, Life Sciences Research Office

Johanna Camara, National Institute of Standards and Technology

Jacek Capala, National Cancer Institute

David Carbone, Vanderbilt University‡

Brian Carey, Foley Hoag LLP

B. Melina Cimler, Beckman Coulter, Inc.‡

Adam Clark, National Cancer Institute

Carolyn Compton, National Cancer Institute†

Rob Danziger, PPD Biomarker Discovery Sciences

Hongue Dai, Rosetta Inpharmatics‡

Felice de Jong, Metabolon, Inc.

Nicholas de Klerk, University of Western Australia

Mark Del Vecchio, Digene Corporation

Nathan Dodder, National Institute of Standards and Technology

James Doroshow, National Cancer Institute*

Elizabeth Dupré, American Enterprise Institute

Mark Fendrick, University of Michigan‡

Suggested Citation:"Appendix B Workshop Speakers, Moderators, Invited Discussants, and Participants." Institute of Medicine. 2006. Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11768.
×

Helen Francis-Lang, Affymetrix

Richard Frank, GE Healthcare‡

Stephen Friend, Merck and Co., Inc.†

Felix Frueh, Food and Drug Administration

Marios Gavrielides, Food and Drug Administration

Robert Gillies, University of Arizona‡

Todd Golub, The Broad Institute of Harvard and MIT*

Mark Gorman, National Coalition for Cancer Survivorship

Steven Gutman, Food and Drug Administration

Susanne Haga, Duke University

Mark A. Heller, Wilmer Cutler Pickering Hale and Dorr*

Judith Hellerstein, University of Maryland‡

Ronald Hendrickson, Merck and Co., Inc.‡

Stuart Hogarth, University of Cambridge

Janet Jamison, National Cancer Institute

Gail Javitt, Genetics and Public Policy Center

Carolyn Jones, Advanced Medical Technology Association (AdvaMed)

Sharon Kim, Precision Therapeutics

Hon-Sum Ko, Food and Drug Administration

Walter Koch, Roche Molecular Systems‡

Paul Lambotte, Quidel Corporation

Michael Leuther, Roche Diagnostics

Rob Lipshutz, Affymetrix*

Donna Marino, HistoRx

Jay Markowitz, T. Rowe Price

Cheryl Marks, National Cancer Institute

Hela Masmoudi, George Washington University

Marilyn Mason, U.S. Department of Veterans Affairs

Lynne McBride, BD Biosciences

Robert McDonough, Aetna U.S. Healthcare†

William T. McGivney, National Comprehensive Cancer Network*†

Steve McPhail, Expression Analysis

Amita Mehratra, National Institutes of Health

Christian Meisel, F. Hoffman-La Roche AG

David Meltzer, University of Chicago*

Zhibao Mi, Precision Therapeutics

Hal Moses, Vanderbilt University†

Juli Murphy, Genetics and Public Policy Center

Ruth Neta, Department of Energy

Nancy Nelson, Journal of the National Cancer Institute

David R. Parkinson, Biogen Idec, Inc.†

Suggested Citation:"Appendix B Workshop Speakers, Moderators, Invited Discussants, and Participants." Institute of Medicine. 2006. Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11768.
×

Scott Patterson, Amgen, Inc.‡

Edith Perez, Mayo Clinic ‡

Omar Perez, Stanford University

Bruce Peterson, PPD Development

Michael E. Phelps, University of California, Los Angeles*

Kathryn Phillips, University of California, San Francisco ‡

William Pignato, W. J. Pignato & Associates

Indra Poola, MD, Howard University‡

M.Suzanne Pursley-Crotteau, National Cancer Institute

John Quackenbush, Harvard School of Public Health*

G.Gregory Raab, Raab & Associates, Inc.

Scott Ramsey, Fred Hutchinson Cancer Research Center†

David Ransohoff, University of North Carolina*†

Eddie Reed, Centers for Disease Control and Prevention

Laura Reid, Expression Analysis‡

Henry Rodriguez, National Cancer Institute

Jim Rollins, Centers for Medicare & Medicaid Services*

Charles L. Sawyers, University of California, Los Angeles*

Richard Schilsky, University of Chicago‡

Jeff Schomisch, Guide to Good Clinical Practice

Howard Schulman, PPD Biomarker Services*†

Katie Schutta, American Society for Clinical Oncology

Yvette Seger, The Center for Accelerating Medical Solutions

Richard M.Simon, National Cancer Institute*†

Dee Simons, Roche Diagnostics

Dominick Sinicropi, Genomic Health, Inc.

Margaret Spitz, MD Anderson Cancer Center‡

Juli Staiano, Foundation for the National Institutes of Health

Andrew Stevens, UK National Institute for Health and Clinical Excellence*

Zoltan Szallasi, Harvard Medical School‡

Brian Taylor, Expression Pathology, Inc.

Samantha Truex, Genzyme Corporation

Gayle Vaday, Congressionally Directed Medical Research Programs

John A. Wagner, Merck Research Laboratories*†

Judith Wagner, Institute of Medicine‡

Paul Waring, Genentech*

Barbara Weber, GlaxoSmithKline‡

Scott Weidman, National Research Council

Jean-Pierre Wery, Eli Lilly and Co.‡

Janet Woodcock, Food and Drug Administration*†

Timothy Yeatman, H. Lee Moffit Cancer Center & Research Institute

Suggested Citation:"Appendix B Workshop Speakers, Moderators, Invited Discussants, and Participants." Institute of Medicine. 2006. Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11768.
×

Brent Zanke, MD, Cancer Care Ontario†

Ann Zauber, Memorial Sloan-Kettering Cancer Center‡

Claire Zhu, National Cancer Institute

Piotr Zien, Advanced Medical Technology Association (AdvaMed)

Suggested Citation:"Appendix B Workshop Speakers, Moderators, Invited Discussants, and Participants." Institute of Medicine. 2006. Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11768.
×
Page 99
Suggested Citation:"Appendix B Workshop Speakers, Moderators, Invited Discussants, and Participants." Institute of Medicine. 2006. Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11768.
×
Page 100
Suggested Citation:"Appendix B Workshop Speakers, Moderators, Invited Discussants, and Participants." Institute of Medicine. 2006. Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11768.
×
Page 101
Suggested Citation:"Appendix B Workshop Speakers, Moderators, Invited Discussants, and Participants." Institute of Medicine. 2006. Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11768.
×
Page 102
Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics: Workshop Summary Get This Book
×
Buy Paperback | $41.00 Buy Ebook | $32.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Research has long sought to identify biomarkers that could detect cancer at an early stage, or predict the optimal cancer therapy for specific patients. Fueling interest in this research are recent technological advances in genomics, proteomics, and metabolomics that can enable researchers to capture the molecular fingerprints of specific cancers and fine-tune their classification according to the molecular defects they harbor. The discovery and development of new markers of cancer could potentially improve cancer screening, diagnosis, and treatment. Given the potential impact cancer biomarkers could have on the cost effectiveness of cancer detection and treatment, they could profoundly alter the economic burden of cancer as well.

Despite the promise of cancer biomarkers, few biomarker-based cancer tests have entered the market, and the translation of research findings on cancer biomarkers into clinically useful tests seems to be lagging. This is perhaps not surprising given the technical, financial, regulatory, and social challenges linked to the discovery, development, validation, and incorporation of biomarker tests into clinical practice.

To explore those challenges and ways to overcome them, the National Cancer Policy Forum held the conference "Developing Biomarker-Based Tools for Cancer Screening, Diagnosis and Treatment: The State of the Science, Evaluation, Implementation, and Economics" in Washington, D.C., from March 20 to 22, 2006.

At this conference, experts gave presentations in one of six sessions. In addition, seven small group discussions explored the policy implications surrounding biomarker development and adoption into clinical practice. Developing Biomarker-based Tools for Developing Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics-Workshop Summary presents the conference proceedings and will be used by an Institute of Medicine (IOM) committee to develop consensus-based recommendations for moving the field of cancer biomarkers forward.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!